Lotus Pharmaceutical is warming up as it prepares to participate for the first time in one of the flagship pharmaceutical fairs of the region, BioTaiwan, which is being held in Taipei from June 29th to July 2nd this year. Andrew Lin, Chairman of Lotus Pharmaceutical, will be attending along with General Manager Jefferson Wang and other members of the Company’s senior management.
The Company is looking forward to showcase its leading edges in the R&D and manufacturing of cytotoxic compounds and softgel capsules. Lotus is also eager to link up with old partners and new contacts at the event, where Lotus will be at booth 301, Zone M, and will appear in various presentation sessions (please see end of this press release for details). With more than 600 participating companies from around the world, this is poised to be an exciting event.
Commenting on participating in BioTaiwan, Lotus General Manager Jefferson Wang said that although BioTaiwan has rarely been the go-to fair for generics companies, Lotus is breaking this stereotype with the marketing and R&D resources across the Alvogen group. He said, “At Lotus, we not only market what we develop and manufacture, we also have a flexible business model to capitalize on consisted of product and portfolio acquisitions, marketing alliances, contract development, and contract manufacturing. That is why we believe BioTaiwan is a good platform for us.”